Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007806 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir
A Phase 1 study, sponsored by Atea Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07007806 is a Phase 1 study that has completed, run by Atea Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT07007806, a Phase 1 study, has completed, sponsored by Atea Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Drug-drug interaction study between Omeprazole and Bemnifosbuvir/Ruzasvir (BEM/RZR)
Interventions
- DRUG Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting
- DRUG Treatment B-Omeprazole 20 mg dose administered fasting
- DRUG Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting
- DRUG Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole
- DRUG Treatment E-Omeprazole 40 mg administered fasting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-05-09 |
| Est. Completion | 2025-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07007806
The ClinicalTrials.gov registry entry for NCT07007806 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atea Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting is the first listed.
NCT07007806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07007806 about?
NCT07007806 is a clinical study titled "Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir". Drug-drug interaction study between Omeprazole and Bemnifosbuvir/Ruzasvir (BEM/RZR)
What is the current status of trial NCT07007806?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-05-09. Estimated completion is 2025-06-28.
What interventions are being tested in trial NCT07007806?
The interventions under investigation include: Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting (DRUG), Treatment B-Omeprazole 20 mg dose administered fasting (DRUG), Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting (DRUG), Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole (DRUG), Treatment E-Omeprazole 40 mg administered fasting (DRUG).
Who is sponsoring clinical trial NCT07007806?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.